The phosphatase activity of soluble epoxide hydrolase as a new target in cardiometabolic diseases

• Applicant: Professor Dr. Eugen Proschak
• Subject Area: Pharmacy ; Biological and Biomimetic Chemistry
• Term: since 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 505561502

Cardiometabolic diseases (CMD) remain the first cause of death worldwide. The newly-identified phosphatase activity of soluble epoxide hydrolase (sEH-P) metabolizes lipid mediators linked to CMD. This projects aims to determine the physiological role of sEH-P and whether its inhibition represents a new therapeutic approach to treat CMD. The proposed network is centred around J. Bellien (Rouen University) that studies the impact of sEH-P knock-in in rats and E. Proschak (Goethe University) that will pursue the development of pharmacological tools enabling selective systemic and central sEH-P inhibition in rodents and humans. After their validation, the impact of these inhibitors will be tested and compared to that of the genetic inactivation in relevant animal models of CMD, with C. Guignabert (University of Paris-Sud) for pulmonary hypertension and cellular mechanistic aspects. Dr. Morisseau (UC Davis) will provide biochemical and analytical support to this project.

• DFG Programme: Research Grants
• International Connection: France
• Partner Organisation: Agence Nationale de la Recherche / The French National Research Agency
• Cooperation Partners: Professor Dr. Jeremy Bellien; Professor Dr. Christophe Guignabert